Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
“We are excited to work with Pierre Fabre, a leader in precision oncology, on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets. Resistance mechanisms, particularly through MAPK reactivation, limit long-term benefit with current standard of care BRAF-targeted treatments. By blocking RAS/MAPK pathway signaling at the most distal node, ERK1/2, ERAS-007 can potentially prevent pathway reactivation.”
Share:
More News
“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing
“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at
“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers
“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.
